• Explore /
  • Poster
  • / Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with <i>mTOR/AKT/PI3K </i>pathway alterations and advanced solid malignancies.

Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.

Abstract Video & Slides Poster

Authors

null

Niamh Coleman

The University of Texas MD Anderson Cancer Center, Houston

Niamh Coleman , Aung Naing , Shizhen Zhang , Sarina Anne Anne Piha-Paul , Apostolia Maria Tsimberidou , Filip Janku , Jordi Rodon , Shubham Pant , Ecaterina Elena Dumbrava , Siqing Fu , David S. Hong , Funda Meric-Bernstam , Vivek Subbiah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT03017833

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3017)

DOI

10.1200/JCO.2021.39.15_suppl.3017

Abstract #

3017

Abstract Disclosures

Similar Posters

First Author: Kathleen N. Moore

First Author: Irene Brana

First Author: V. Moreno Garcia

First Author: Sun Young Rha